Last updated on September 2018

A Phase 3 clinical study for patients with Mesothelioma

Brief description of study

This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.

Clinical Study Identifier: NCT01907100

Contact Investigators or Research Sites near you

Start Over

Wilgers Oncology Centre
Pretoria, South Africa